{"id":"W3095376160","doi":"10.1182/blood-2020-136571","title":"Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"CD137; Cancer research; T cell; CD19; Antibody-dependent cell-mediated cytotoxicity; Immunotherapy; Immunology; Antigen; Medicine; Antibody; Immune system; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001068285,0.001769451,0.001741295,0.0004751633,0.0004615249,0.001173986,0.0009927026,0.001597102,0.00332913],"category_scores_gemma":[0.0004534819,0.0007224174,0.001079184,0.0002958262,0.0006596089,0.0006719521,0.0003536447,0.002892311,0.001318183],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001033894,"about_ca_system_score_gemma":0.001813534,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001332396,"about_ca_topic_score_gemma":0.002785135,"domain_scores_codex":[0.9996746,0.0001050611,0.000009960215,0.00007344921,0.00003737035,0.00009948848],"domain_scores_gemma":[0.9997171,0.00002981341,0.00004709169,0.00002617226,0.00002959633,0.0001502637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3562167,0.2208631,0.006755688,0.001527237,0.002180663,0.000960924,0.0007721193,0.00622081,0.2558398,0.0009763807,0.0163581,0.1313286],"study_design_scores_gemma":[0.2673029,0.6964649,0.007957948,0.00006310001,0.0006265314,0.0006995231,0.00008923139,0.001632487,0.016471,0.0004998732,0.008150259,0.00004227073],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843184,0.003236479,0.001547467,0.0005800628,0.0001593318,0.004764153,0.002449872,0.0002084692,0.002735806],"genre_scores_gemma":[0.9747511,0.004009708,0.002770991,0.001322554,0.0001682077,0.005849648,0.004773194,0.00009693075,0.006257688],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00332913,"threshold_uncertainty_score":0.01113707,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01726297855213852,"score_gpt":0.29514716114276,"score_spread":0.2778841825906214,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}